# Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

> **NCT07044544** · PHASE1 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 20 (estimated)

## Conditions studied

- Myeloid Malignancy
- Hematologic Malignancy
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** G-CSF
- **DRUG:** Decitabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07044544
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-17
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044544, "Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07044544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*